NovaBridge Biosciences
NBP | NASDAQ
$1.61
+$0.01 (+0.63%)
At close: Sep 21, 2026, 4:00 PM ET
$1.61
$0 (0.00%)
Pre-market:
Sep 22, 2026, 7:12 AM ET
+0.63%
(1D)Rating
Updated: Sep 19, 2026Key Statistics
Market Data
Market Cap $185.58M
1D Range
1.61 1.64
52W Range
1.46 6.79
Valuation (TTM)
PE -2.78
PB 0.92
EV/EBITDA 0.01
Valuation (NTM)
Forward PE N/A
Forward PEG -0.38
Price Target $8.25
Cash Flow
FCF Yield -19.0%
SBC Adj. FCF Yield -30.4%
SBC Impact -59.8%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y -150.0% |
-37.0%
Dil EPS 3Y | 5Y 128.2% |
60.8%
FCF 3Y | 5Y -150.0% |
76.1%
Returns
ROA -21.2%
ROE -1.4%
ROIC -29.0%
Financial Health
Net Cash
$190.85M
Current Ratio 7.64
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several signifi...
Sector Healthcare
Industry Biotechnology
Employees 30
IPO Date Jan 16, 2020
Website www.novabridge.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$8.50
Upside
+427.95%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove NBP